OTC : AMGXF

AnGes, Inc.

$0.3602 USD

$0 (0.0%)

Volume
618
Average Volume
458.22
Market Capitalization
$142.5M
P/E Ratio
-3.40
Dividend Yield
0.00%
Price Target
Year High
$0.36
Year Low
$0.34
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.97
Company Overview

OTC

Ei Yamada

Biotechnology

Healthcare

AMGXF

56

JP

USD

https://www.anges.co.jp

+81 72 641 8011

N/A

N/A

Liquidity Metrics

0.34

1.97

1.00

0.49

0.00

Sales & Valuation

$874.88M

20.90

9.37

0.00

0.00

Profitability

-$14.45

-$5.13B

-545.66%

-562.28%

-156.47%

-110.87%

P/E Metrics

-3.40

-0.03

-0.03

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Poll Results

About AnGes, Inc. (OTC:AMGXF) Stock

AnGes, Inc., a biopharmaceutical firm established in 1999 and headquartered in Ibaraki, Japan, specializes in the research and advancement of gene-based medical solutions. The company's flagship product is Hepatocyte Growth Factor (HGF) Plasmid, a pioneering gene therapy developed to address critical limb ischemia, a severe condition characterized by impaired blood circulation in the legs. Beyond its lead therapy, AnGes is progressing a diverse portfolio of treatments. This includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine designed to mitigate inflammation, which is being investigated for ailments such as low back pain. The company is also working on therapies for atopic dermatitis and disc degeneration, alongside medical devices aimed at preventing vascular restenosis. Their e ... fforts extend to the vaccine sector, encompassing therapeutic vaccines for cervical intraepithelial neoplasia (a precursor to cervical cancer), and DNA vaccines for high blood pressure, developed through a collaboration with Osaka University. Furthermore, AnGes is involved in multiple initiatives for coronavirus vaccines, including a partnership with Osaka University and an investigational plasmid DNA vaccine project with Brickell Biotech, Inc., targeting markets in the United States, South America, and elsewhere. To expand its commercial reach and development capabilities, AnGes has forged several strategic alliances. It collaborates with BioMarin Pharmaceutical Inc. for the Japanese marketing of Naglazyme, a drug for mucopolysaccharidosis VI. AnGes also partners with Mitsubishi Tanabe Pharma Corporation to market HGF Plasmid for peripheral arterial disease in the U.S. and Japan. Other key partnerships include SHIONOGI & CO., LTD. for the distribution of external-use drugs containing NF-kB decoy oligonucleotide for skin conditions, and Vical, Inc. for the development and commercialization of Allovectin, a cancer treatment. The company, originally known as AnGes MG, Inc., officially adopted the name AnGes, Inc. in July 2017, continuing its commitment to innovation in gene-based medicine.

Frequently Asked Questions

What is the current AnGes, Inc. (AMGXF) stock price?

AnGes, Inc.(OTC:AMGXF) stock price is $0.3602 in the last trading session. During the trading session, AMGXF stock reached the peak price of $0.3602 while $0.3353 was the lowest point it dropped to. The percentage change in AMGXF stock occurred in the recent session was 0.0% while the dollar amount for the price change in AMGXF stock was $0.

AMGXF's industry and sector of operation?

The OTC listed AMGXF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of AMGXF?

Ei Yamada | Chief Executive Officer, President & Representative Director
Naoya Sato | Director of Administration & Director
Yuka Murakami | Accounting Department Manager
|
|

How many employees does AMGXF have?

Number of AMGXF employees currently stands at 56. AMGXF operates from Saito Bio-Incubator, Ibaraki, OS 567-0085, JP.

Link for AMGXF official website?

Official Website of AMGXF is: https://www.anges.co.jp

How do I contact AMGXF?

AMGXF could be contacted at phone #+81 72 641 8011 and can also be accessed through its website. AMGXF operates from Saito Bio-Incubator, Ibaraki, OS 567-0085, JP.

How many shares of AMGXF are traded daily?

The average number of AMGXF shares traded daily for last 3 months was 458.22.

What is the market cap of AMGXF currently?

The market value of AMGXF currently stands at $142.5M with its latest stock price at $0.3602